Tubulis GmbH
Reimagining ADCs.
Reimagining ADCs.
Tubulis GmbH is a biotechnology startup based in Germany. Founded in 2019, the company is focused on reimagining antibody drug conjugates (ADCs) through its proprietary technologies and disease-specific biology. Tubulis® aims to expand the therapeutic potential of ADCs, delivering better outcomes for patients by generating uniquely matched protein-drug conjugates. The company's vision is to advance a diverse range of conjugates, unrestricted by indication, utilizing its own discovery capabilities and overcoming development challenges for partners with both antibody and chemical assets.
In March 2024, Tubulis GmbH successfully closed a significant €128.00M Series B investment round, demonstrating investor confidence in its innovative approach and potential for impact. The funding was secured from a notable group of investors including Bayern Kapital, Seventure Partners, BioMed Partners, Coparion, Evotec, Fund+, Nextech Invest, Occident, Frazier Life Sciences, and HTGF | High-Tech Gruenderfonds.
With its robust funding and strategic investor support, Tubulis GmbH is well positioned to pursue its mission of revolutionizing ADCs and making strides in the fields of biotechnology, healthcare, life sciences, and pharmaceuticals.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | €128.00M | 10 |
|
14 Mar 2024 |
| Series B | €60.00M | 9 |
|
03 May 2022 |
| Series A | €10.70M | 6 |
|
21 Jul 2020 |
| Grant | €1.30M | - | 10 Jul 2017 |
No recent news or press coverage available for Tubulis GmbH.
We care about your data, and we'd love to use cookies make your experience better.
